GlassScriptPhysician profile
Khaled Refaai Mohamed Refaai
NPI 1033859368
$1,201.57
in general payments reported to CMS, 2019-2025
14 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $343 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $371.76 | 2024-2025 | Signia, Aquamantys(Tm), Plasmablade(Tm) |
| C. R. Bard, INC. & Subsidiaries | $190.37 | 2025 | Bard Urinary Drainage Bag |
| Integra Lifesciences Corporation | $169.70 | 2025 | Codman Certas, Cusa Clarity, Codman Hakim |
| Dilon Technologies, INC. | $141.82 | 2025 | Hemoblast Bellows |
| Paragonix Technologies, INC. | $69.27 | 2025 | Kidneyvault |
| Baxter Healthcare | $62.89 | 2024 | Perclot |
| Procept Biorobotics Corporation | $51.41 | 2024-2025 | Aquabeam System |
| Axogen | $32.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.27 | 2024 | |
| Myriad Genetic Laboratories, INC. | $21.29 | 2025 | Myrisk |
| Accord Healthcare, INC. | $17.01 | 2025 | |
| Immunitybio, INC. | $16.85 | 2025 | |
| Urogen Pharma, INC. | $15.77 | 2025 | |
| Janssen Biotech, INC. | $14.98 | 2025 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Refaai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.